Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
Schiller
GLOBETECH PUBLISHING LLC

Molecular Imaging Tracers Help Determine Brain Metastases Treatment Strategies

By Medimaging International staff writers
Posted on 17 Dec 2013
Imaging with the molecular imaging tracer 18F-FDOPA (L-3,4-dihydroxy-6-[18F]fluoro-phenylalanine) can help differentiate radiation-induced lesions from new tumor growth in patients who have been treated with radiotherapy for brain metastases, according to new research.

Using this amino acid tracer, researchers discovered that physicians could effectively differentiate the two types of lesions 83% of the time. Progression-free survival could also be predicted through evaluating the 18F-FDOPA imaging findings.

Brain metastases occur in 20%–40% of all cancer patients, especially in those with melanoma, non-small-cell lung cancer, and breast cancer. They account for 170,000 new cases yearly in the United States alone, and prognosis is poor. Treatment for brain metastases usually includes a combination of surgery, radiation treatment, and chemotherapy.

“Histopathological changes in neural tissue treated with radiation could trigger clinical and imaging manifestations which are very similar to those caused by tumor growth,” said Karlo J. Lizarraga, MD, MS, from the department of neurology, Miller School of Medicine, University of Miami (FL, USA), and lead author of the study. “The challenge is then to differentiate whether these manifestations are due to radiation or to tumor progression or recurrence. Accurate and timely distinction between these two possibilities can significantly affect patient care, and outcome for treatment modalities are completely different for each case.”

In the retrospective study, published ahead of print October 28, 2013, and slated for the January 1, 2014, issue of the Journal of Nuclear Medicine, researchers analyzed images from 32 patients who had 83 earlier irradiated brain metastases and who underwent 18F-FDOPA positron emission tomography (PET). The studies were analyzed both semi-quantitatively and visually to determine whether lesions were caused by radiation injury or were recurrent or progressive brain metastases. Results were verified by histopathologic analysis or clinical follow-up. The prognostic ability of 18F-FDOPA in predicting progression-free survival and overall survival was also studied with the Kaplan-Meier and Cox regression techniques.

The best overall accuracy for differentiating between the two types of lesions was achieved using visual scoring, which had a sensitivity of 81.3%, a specificity of 84.3%, and an overall accuracy of 83.1%. The semi-quantitative analysis resulted in a sensitivity of 81.3%, a specificity of 72.5% and an overall accuracy of 75.9%.

Researchers also discovered that evaluations with 18F-FDOPA PET was highly prognostic of progression-free survival, as lesions with a negative PET result had a mean time to progression that was 4.6 times longer than lesions with positive 18F-FDOPA PET findings. Moreover, a trend toward predicting overall survival was also seen.

18F-FDOPA PET imaging is currently available in few centers. The longer physical half-life of 18F-FDOPA, when compared to other amino acid tracers, gives it the advantage of potential automated production and transport to PET centers for widespread use,” noted Dr. Lizarraga.

Related Links:

Miller School of Medicine, University of Miami



Channels

Radiography

view channel

Pediatric Radiation Dose Reduction Key Factor in Selection of DR Systems

X-Ray dose reduction potential was a key factor in the decision of the Washington DC (USA) metropolitan area Children’s National Health System to install new Direct Radiography (DR) systems. The priority of Children’s National Health System was to ensure that pediatric patients would receive the lowest possible dose... Read more

MRI

view channel
Image: The Micronor M303 Encoding Sensor with A/B Quadrature Pulse Train Background (Photo courtesy of Micronor).

World’s First MRI-Safe Linear Encoder for Medical Applications Announced

A company specialized in producing fiber optic kinetic sensors, has developed a first-of-a-kind passive, optical, non-electronic, high-precision encoder for use in medical Magnetic Resonance Imaging (MRI).... Read more

Ultrasound

view channel
Image: The Lumify, app-based ultrasound system (Photo courtesy of Philips).

Philips Debuts First App-Based Ultrasound

An app-based ultrasound solution aims extending the reach of ultrasound applications using mobile technology. The app was presented at the Social Media and Critical Care conference, June, 23–26, 2015... Read more

General/Advanced Imaging

view channel

FDA Approves Trial for Intraoperative Image-Guided Cancer Surgery System

The US Food and Drug Administration (FDA) has provided Investigational Device Exemption (IDE) approval for company to trial a new image-guided cancer surgery system for intraoperative imaging of breast cancer. The surgical system consists of a cancer-specific molecular imaging agent, and a lightweight hand-held single-cell... Read more

Imaging IT

view channel
Image: CT Vitality is available on Aquilion ONE systems and provides remote management of CT Protocols and data capture (Photo courtesy of Toshiba America Medical Systems).

Breakthrough Software Manages CT Protocols

A first-of-a-kind software that can automate Computed Tomography (CT) protocol management has been released by a major medical imaging vendor. The novel software application improves the efficiency... Read more

Industry News

view channel

Therapeutic Ultrasound Manufacturer Announces First Transaction in Egypt

Theraclion (Malakoff, France) made the first sale of its Echopulse ecotherapy system in Egypt to EgyHiFu (Cairo, Egypt), a clinic that specializes in treating abdominal and prostate tumors using high-intensity focused ultrasound (HIFU). The company is certified by the International Organization for Standardization (ISO)... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.